{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "DKK", "marketState": "CLOSED", "regularMarketChangePercent": 5.526123, "regularMarketPrice": 418.2, "exchange": "CXE", "shortName": "Chemometec A/S", "longName": "ChemoMetec A/S", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "regularMarketTime": 1683899453, "earningsTimestamp": 1683629940, "earningsTimestampStart": 1683629940, "earningsTimestampEnd": 1683629940, "trailingAnnualDividendRate": 0.0, "trailingPE": 40.601944, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 10.3, "sharesOutstanding": 17402500, "bookValue": 26.272, "fiftyDayAverage": 378.625, "fiftyDayAverageChange": 39.575012, "fiftyDayAverageChangePercent": 0.10452298, "twoHundredDayAverage": 378.625, "twoHundredDayAverageChange": 39.575012, "twoHundredDayAverageChangePercent": 0.10452298, "marketCap": 7518274560, "priceToBook": 15.918089, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1430722800000, "priceHint": 2, "regularMarketChange": 21.900024, "regularMarketDayHigh": 418.2, "regularMarketDayRange": "418.2 - 418.2", "regularMarketDayLow": 418.2, "regularMarketVolume": 1, "regularMarketPreviousClose": 396.3, "bid": 418.2, "ask": 0.0, "fullExchangeName": "Cboe UK", "financialCurrency": "DKK", "regularMarketOpen": 418.2, "averageDailyVolume3Month": 91, "averageDailyVolume10Day": 91, "fiftyTwoWeekLowChange": 72.0, "fiftyTwoWeekLowChangePercent": 0.20797226, "fiftyTwoWeekRange": "346.2 - 418.2", "fiftyTwoWeekHighChange": 0.0, "fiftyTwoWeekHighChangePercent": 0.0, "fiftyTwoWeekLow": 346.2, "fiftyTwoWeekHigh": 418.2, "symbol": "CHEMMC.XC"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Gydevang 43", "city": "Aller\u00f8d", "zip": "3450", "country": "Denmark", "phone": "45 48 13 10 20", "website": "https://chemometec.com", "industry": "Scientific & Technical Instruments", "industryDisp": "Scientific & Technical Instruments", "sector": "Technology", "longBusinessSummary": "ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in are areas of cell-based therapy, cancer, and stem cell research, development, and manufacturing of pharmaceuticals as well as production and quality control of animal semen and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal production; NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample; and NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension. It also provides consumables comprising cassettes, reagents, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans. The company was incorporated in 1997 and is headquartered in Aller\u00f8d, Denmark.", "fullTimeEmployees": 162, "companyOfficers": [{"maxAge": 1, "name": "Mr. Hans Martin Glensbjerg", "age": 63, "title": "Vice Chairman & COO", "yearBorn": 1959, "fiscalYear": 2019, "totalPay": {"raw": 20000, "fmt": "20k", "longFmt": "20,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Steen  Sondergaard", "age": 63, "title": "Chief Exec. Officer", "yearBorn": 1959, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Niels Hoy Nielsen", "title": "Chief Financial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lisbet  Helles", "title": "Head of Marketing", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. S\u00f8ren  Kj\u00e6rulff", "title": "Head of R&D", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Michael  Packert", "title": "Head of Production", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Christopher  Runchel M.Sc., Ph.D.", "title": "Sr. VP of US", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Martin Helbo Behrens", "title": "Chief Financial Officer of US", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Kenneth Kaiser Paustian", "title": "Head of Fin.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 1, "overallRisk": 10, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1577750400, "maxAge": 86400}}], "error": null}}